The ODAC vote on March 22 (which was not a vote on the drug itself) sent the SP falling 35% or so. It is not really indicative of any company "wipeout".
check www.chemgenex.com
the website will provide you with information of where the company is currently at in terms of their NDA for Omapro.
The next step is a Type A meeting with the FDA in June to discuss the concerns over study size, vial size of the drug, and the T315I diagnostic. It certainly isn't the end of the road for CXS. Just more hurdles in the way of getting the drug approved.
A lot of drug companies get knocked back from the FDA with their initial NDA submissions. CXS has more work to do to get this approved.
Add to My Watchlist
What is My Watchlist?